Pharmaceutical Giants Compete in Developing Weight-Loss Pills.

Eli Lilly is gaining an edge over Novo Nordisk in the race to supply obesity drugs, after showcasing a slew of promising new treatments at the American Diabetes Association conference. The Indianapolis-based drugmaker dropped results from successful trials, including an effective obesity pill, the use of its diabetes drug Mounjaro in weight loss, and a highly anticipated injectable that cut the most weight seen with any obesity drug. Novo Nordisk's Ozempic and Wegovy had set off a new era in obesity medicine, delivering unprecedented levels of weight loss.